Erasca(ERAS)
SAN DIEGO, CABiotechnology
Focus: Erasca is a public oncology-focused biotech company developing targeted cancer therapies, primarily RAS pathway inhibitors and related precision medicines. The company operates as a clinical-stage innovator with a diversified pipeline across multiple solid tumors and hematologic malignancies.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
7
Should You Work at Erasca?
AI assessmentErasca offers upside optionality in precision oncology with recent regulatory momentum, but deteriorating cash and minimal hiring signal a cautious growth phase—suitable for risk-tolerant researchers betting on clinical wins.
Why Work Here
- Recently secured FDA Fast Track designation for ERAS-0015 (pan-RAS drug) with 57% preliminary response in KRAS G12X pancreatic cancer, signaling near-term value inflection.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ERAS-4001
Metastatic Solid TumorsClinical Trials (1)
NCT07021898A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
Phase 1Help build intelligence for Erasca
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.